Amarin Corp Plc (AMRN)

[Biobillionair]

Rose- You bring up a point that is disturbingly actionable.

Well, quite a different take on API supply compared to what JT and many here on the board have been saying.

Amarin August Investor slide deck page 14

? If VASCEPA goes generic in US, sales of VASCEPA by Amarin are likely to continue at meaningful level for a substantial period of time
? Historically VASCEPA has been challenging and expensive to learn to produce cost- effectively with consistent high quality at commercial scale
? Amarin has proven manufacturing capacity with costs of goods which have lowered with experience and scale
? At least initially, the capacity of generic VASCEPA which is anticipated to be insufficient to fully supply market demand and capacity expansion is typically expensive and time- consuming
? Amarin share of branded and/or authorized generic to be influenced by generic capacity

https://investor.amarincorp.com/static-files/d6b5bb48-f4f6-4d84-b565-37abd27d3f6a

BB